Program
Dolutegravir
Also written as “GSK1349572”, “DTG” and “Dolutegravir 50 mg”.
Its studies are mostly in Infections · HIV Infections · Malaria · Acquired Immunodeficiency Syndrome · Tuberculosis, led by 3 companies.
Drug pageDolutegravir: every studyAll 170 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 643 open or running | phase 4since Oct 13, 2017 | Nov 5, 2007 | Sep 14, 2032phase 3 · NCT07393659 |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jun 4, 2024 | Jun 4, 2024 | none ahead |
| Viatris | 10 open or running | early phase 1since Jul 28, 2021 | Jul 28, 2021 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Johnson & Johnson and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2021First study: early phase 1 study in HIV-1-infectionFirst studyNCT05030025 · 43 enrolled · Canada
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
The one study Viatris leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05030025HIV-1-infection · Canada | Early 1 | Completed | Aug 29, 2021 | 43 |
How it is read
Names in the registry
- “GSK1349572”, 20 entries
- “Dolutegravir”, 12 entries
- “DTG”, 6 entries
- “Dolutegravir 50 mg”, 4 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- Infections, 31 studies
- HIV Infections, 25 studies
- Malaria, 1 study
- Acquired Immunodeficiency Syndrome, 1 study
- Tuberculosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.